ArticleBMC infectious diseases2026
Association between dietary zinc intake and herpes simplex virus seropositivity in U.S. adults: a cross-sectional study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAlthough recent research has demonstrated an association between serum zinc deficiency and susceptibility to various viral infections, the relationship between dietary zinc intake and herpes simplex virus (HSV) seropositivity remains unclear.
methodsThe National Health and Nutrition Examination Survey (NHANES) (2007–2016) provides data on HSV-1 and HSV-2 status and dietary zinc intake. The associations between dietary zinc and HSV-1 and HSV-2 were evaluated via various statistical methods, including multivariate logistic regression, restricted cubic spline analysis, and subgroup analysis.
resultsIn total, 6,483 individuals were enrolled, with 58.9% (3,817/6,483) testing positive for HSV-1 and 19.3% (1,253/6,483) testing positive for HSV-2. After adjusting for all covariates in the multivariate logistic regression, compared with the lowest zinc intake group (Q1: <7.51 mg/day), the adjusted odds ratios (ORs) for HSV-1 and HSV-2 in the higher-zinc intake groups were as follows: for HSV-1, Q2 (7.51–10.87 mg/day) had an OR of 0.81 (95% confidence interval [CI]: 0.72–0.98, p = 0.027), and Q3 (10.87–15.63 mg/day) had an OR of 0.85 (95% CI: 0.70–1.03, p = 0.093), and Q4 (> 15.63 mg/day) had an OR of 0.84 (95% CI: 0.67–1.04, p = 0.114); for HSV-2, Q2 had an OR of 0.80 (95% CI: 0.64–1.00, p = 0.050), Q3 had an OR of 0.81 (95% CI: 0.64–1.02, p = 0.069), and Q4 had an OR of 0.75 (95.
conclusionDietary zinc intake exhibited a U-shaped association with HSV-1 and HSV-2 seropositivity, indicating that moderate zinc intake has a protective effect. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.